Delayed–release dimethyl fumarate (DMF), Tecfidera®, is approved globally for treating
relapsing-remitting multiple sclerosis. The disposition of DMF was determined in humans …

Dimethyl fumarate (DMF) is a first-line prodrug for the treatment of relapsing-remitting
multiple sclerosis (RRMS) that is completely metabolized to monomethyl fumarate (MMF) …

Background Tecfidera®(dimethyl fumarate [DMF]) is an approved product for the treatment
of relapsing forms of multiple sclerosis. Monomethyl fumarate (MMF) is the only active …

Background Delayed-release dimethyl fumarate (DR-DMF) has cytoprotective and
antiinflammatory properties and has recently been approved in the United States as an oral …

Background Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for
relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the …

Dimethyl fumarate (DMF) is approved for the treatment of relapsing-remitting multiple
sclerosis. It is unknown whether DMF or its primary metabolite monomethyl fumarate (MMF) …

Background Monomethyl fumarate (MMF) is the pharmacologically active metabolite of
dimethyl fumarate (DMF). MMF formulated as Bafiertam™ 190 mg and DMF formulated as …

Dimethyl fumarate (Tecfidera®) is a novel oral therapy that has recently been approved for
the treatment of relapsing forms of multiple sclerosis (MS) and relapsing-remitting MS …

Dimethyl fumarate (Tecfidera®) is approved for the treatment of relapsing forms of multiple
sclerosis (MS). Based on evidence from the clinical trial and real-world settings, dimethyl …

Dimethylfumarate (DMF) has long been used as part of a fixed combination of fumaric acid
esters (FAE) in some European countries and is now available as an oral monotherapy for …